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Glioblastoma (GBM) is the most common, lethal and aggressive brain tumor in adults.
Standard treatment involves surgery, radiation therapy and temozolomide (TMZ) chemotherapy.
However, GBM recurs and the average survival rate is between 12 to 18 months with 25% 1year survival rate and 9% 5 years survival rate. Treatment options and advancement is limited by
the blood brain barrier (BBB) which restricts drug entry into the brain and the immense
heterogeneity of the tumor which limit adequate control of the entire tumor using one drug. In
this research, we explored whether a combination mixture of TMZ and non-steroidal antiinflammatory drugs (NSAIDs) which have shown anticancer properties (diclofenac, aspirin,
ibuprofen, ketoprofen, naproxen, oxaproxin) may have synergistic or additive effects on U87MG
cell line. All the combination mixtures in the ratio 1:1 had a lower LC50 value compared to
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individual compounds indicating that combination mixtures could have a synergistic or additive
effect against GBM. We also examined whether novel hybrid of diclofenac (which had the
lowest LC50 value, cell motility changes and morphological changes) and purines (which have
shown to be able to enhance TMZ antitumor efficacy) could have a higher efficacy compared to
individual compounds. All the novel hybrids of diclofenac and purines had lower LC50 compared
to individual compounds. Therefore, hybrids and mixtures could have a higher efficacy and a
better promise to GBM patients.
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CHAPTER 1

INTRODUCTION
Research goal: To investigate the efficacy of mixtures and hybrids of
temozolomide (TMZ) and non-steroidal anti-inflammatory drugs (NSAIDs), and amino purines
(AP) against glioblastoma multiforme (GBM).

Cancer
Cancer refers to a group of more than 100 diseases that develop over time, are
characterized by uncontrolled cell division, growth and metastatic properties. Though cancer can
develop in any part of the body’s tissues, and each type of cancer disease is unique, the basic
processes that lead to development of cancer are similar[1].
Cancer develops from a cell that stops responding to normal cell division restraints then
begins to proliferate continuously [1]. Daughter cells from this parent cancerous cell also show
abnormal and inappropriate proliferation. Continued cell division leads to formation of a mass of
cells called a tumor. Though tumors begin with a single cell, at the time of clinical diagnosis,
majority of the tumors show startling heterogeneity in morphological and physiological features
such as angiogenic and proliferative potential[2]. Inter tumor heterogeneity is characterized by
distinct genetic alterations which occur in individual tumors that originate from the same organ
while intratumor heterogeneity is characterized by genetic alterations within individual
tumors[3]. Heterogeneity is a hallmark is some cancers like glioblastoma multiforme (GBM)
which have pronounced heterogeneity on histological, genetic and gene expression levels[4].
This is why single drug therapies do not show significant benefit on GBM patients[5].
1

Some tumors remain within the tissue it originated. These are called benign tumors.
Tumors which develop metastatic properties, attributed by down-regulation of cell adhesion
receptors and up-regulation of receptors enhancing cell motility, are said to be malignant. The
abnormal tumor growth becomes life threatening when they disturb the normal tissue and organ
functions[1, 6, 7].
There are a number of differences between cancer cells and normal cells. Below is a table
with a list of notable differences.
Table 1:Comparison between normal cells and cancer cells
Normal cells

Cancer cells

Controlled by external growth signals

Do not depend on external growth signals.

Most do not move around the body

Can move around the body

They stop growing when they encounter

Invade and spread to other areas of the body

other cells
Can be eliminated by the immune system

Hide from the immune system

when damaged or abnormal
Do not have multiple changes in

Accumulates multiple changes in

chromosomes

chromosomes

Its growth is controlled

Growth rate is uncontrolled

Cell shape is uniform

Cell shape irregular

Has single nucleus

Has multiple nucleus

Has spheroid nucleus

Nucleus take multiple shapes
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Has fine distributed chromatin

Have coarse and aggregated chromatin

Always mature into very specialized cells

Remain immature

They favor aerobic respiration

Favor anaerobic respiration

Figure 1:Cancer hallmarks. Cancer characteristics common in all cancer cells

In 2000, two cancer researchers named Douglas Hanahan, founding member of
Whitehead Institute and Robert Weinberg, Director of the Swiss Institute for Experimental
Research, proposed six cancer hallmarks. Together, these six cancer hallmarks (figure 1)
constituted an organizing principle that provided a logical framework for understanding the
highly diverse types of cancer diseases. They include sustaining proliferative signaling, evading
growth suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis,
and activating invasion and metastasis[8]. Benign and malignant tumors share all the hallmarks
except invasion and metastasis[9]. Behind all these hallmarks are genomic instabilities in the
cancer cells which are responsible for the genetic diversities[10]. In 2011, a decade later,
Douglas Hanahan and Robert A. Weinberg introduced two enabling characteristics into the
3

cancer hallmark canon. These characteristics include genome instability and mutation[11-13],
and tumor promoting inflammation[14-17].
In this research, we investigate the efficacy of drug mixtures and hybrids to address cell
proliferation and inflammation associated with GBM. The specific questions we address are: a)
could physical mixtures of temozolomide (a drug targeting cell proliferation) and non-steroidal
anti-inflammatory drugs (NSAIDs) which target inflammation have a higher efficacy? b) TMZ is
a current first line chemotherapeutic drug given to (GBM) patients. Could addition of NSAIDs
drugs which act against an enabling factor (tumor promoting inflammation), be a better and
promising strategy in GBM treatment?

Glioblastoma multiforme (GBM)
Glioblastoma multiforme (GBM) is the most common, most devastating, the most fatal
primary brain tumor[18]. It is highly aggressive, progressive and invasive, often invading the
brain parenchyma then progressing through corpus callosum into other parts of cerebral
hemispheres [19]. Its highly invasive nature currently represents the most challenging hurdle to
surgical resection[20].
GBM is an astrocytoma. Astrocytoma is a brain tumor that develop from glial cells called
astrocytes. They are classified into four grades. Grade I astrocytoma is a localized tumor that can
be removed surgically, and they can be cured. They have a high prognosis and are considered
low-grade neoplasms. An example is pilocytic astrocytoma[21]. Grade II astrocytoma are
malignant and invasive but not to the extent of higher grades. An example is fibrillary
astrocytoma[22]. Grade III astrocytoma is a highly invasive and malignant. Moreover, they have
a poor prognosis. An example of grade III astrocytoma is anaplastic astrocytoma. Glioblastoma
is a grade IV astrocytoma. Very resistant to therapies, the most aggressive and malignant[23, 24].
4

There are two different classifications of GBM. Primary, which arise without a known precursor
and secondary where low grade tumor transforms into GBM. Primary GBM are more common,
occur in older aged people and have poorer prognosis compared to secondary GBM[25].
In 2020, American Society for Clinical Oncology (ASCO) estimated that 23,890 adults
and 3,540 children would be diagnosed with primary brain tumors in America. Glioblastoma
multiforme (GBM) represents 15-20% of primary brain tumors, 48 % of primary malignant
tumors of the central nervous system and 57 % of all gliomas. Moreover, the highest number of
people diagnosed with GBM are aged between 75-80 years and the median age at diagnosis is
64[26, 27].
GBM is initially difficult to detect since the symptoms vary among patients and depend
on the tumor’s size and location in the brain [18]. Some of the more common general symptoms
include headaches, changes in mood and personality, and seizures. Patients who show an
increase in intercranial pressure as a result of the rapid growth of the tumor typically will
experience nausea and vomiting as well as headaches and seizures [28]. As the tumor grows,
there is also indication of neurological damage by aphasia, sensory loss, and hemianopsia [29].
When the neurological symptoms become more apparent, such as the seizures and personality
changes, the patient will most likely have to undergo a head CT or MRI scan [28]. At this point,
the GBM will be at stage four.
There are many challenges when it comes to treatment of GBM e.g. rapid tumor
progression, intra and inter-tumor heterogeneity, tumor location that is hard to reach, the blood
brain barrier that limits drug efficacy and tumor relapse. This is why mortality rates remain high.
Over the past decade, there have been improvements in surgical approaches, chemotherapy and
radiotherapy. These improvements have led to slight improvements in survival rates as well as
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quality of life for GBM patients. However, prognosis is still a major issue [30] Currently,
management of GBM patients is more inclusive, in that, therapeutic management is offered
alongside effective supportive care. Therapeutic management involves administration of antitumor drugs while supportive care involves the management of signs and symptoms. These signs
and symptoms include seizures, cognitive impairment, edema, osteoporosis, venous
thromboembolism, mood disorders as well as gastrointestinal tract disturbances among
others[31]. Supportive care is aimed at improving the quality of life. Some of the drugs
administered as supportive care medicine include corticosteroids and Dexamethasone for
symptomatic relief and Levitiracetam for seizures[32]. Therapeutic management involves
surgery followed by radiation therapy and chemotherapy.
Surgery remains the principal part of standard care for GBM patients[33]. Surgery can
be used to reduce the tumor burden, control seizures, reverse neurological deficits and introduce
local therapeutic agents. There are limitations on the extent to which resections can be done.
These limitations are dependent on the site of the tumor and eloquence of the brain area. Sites
like basal ganglia, brain stem and cortex have very poor prognosis and may not be amenable to
surgical resections. Unfortunately, patients inevitably face recurrence often 2-3 cm from the
margin of the previous lesion[34, 35]. This is because GBM is highly invasive making it almost
impossible to eliminate through surgical resection. GBM cells interact with many different cells
in the brain including endothelial cells, astrocytes, neurons and extracellular matrix (ECM).
Interestingly, it has been shown that it can shrink its cell body to infiltrate into narrow spaces of
the brain, thereby invading many different regions of the brain and escaping from surgery[36].
The main process involved not only in invasion but also in metastasis is epithelial to
mesenchymal transition (EMT), whereby cells lose cell to cell adhesion, polarity and the
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expression of cell surface and cytoskeletal proteins, thus enabling cells to acquire migratory
properties[37].
GBM response to radiation varies from patient to patient. In many cases, it induces a
phase of remission seen in the reduction of the tumor size. However, this phase of remission is
often short since the tumor recurs [38]. Research has shown that combination of surgery,
radiation therapy and chemotherapy prolong the survival rates of GBM, that is, when compared
with surgery alone. Radiotherapy and surgery increase the survival rates from 4 months to 12
month[39]. Radiation dose of up to 4500 cGy in GBM patients results in median survival rate of
13 weeks while a radiation dose of 6000 cGy administered 5 days every week (1.8 -2 cGy per
day) results in a median survival of 42 week[40].
In this research, we are investigating chemotherapeutic mode of treatment using TMZ
which is a first line drug given to GBM patients in combination with NSAIDs.

Temozolomide
Temozolomide (TMZ) was first synthesized in the late 1970s but was FDA approved for
medical use in 1999 to treat refractory anaplastic astrocytoma[41, 42] and glioblastoma
multiforme (GBM) in 2005 [43]. TMZ is an imidazotetrazine lipophilic prodrug which can cross
through the blood
brain barrier hence
it can be
administered
orally. It is stable in
acidic pH but at pH
higher than 7, TMZ is spontaneously

Figure 2: Conversion of temozolomide (TMZ) to 5-(3-methyltriazen-1-yl)
imidazole-4-carboxamide (MTIC)
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hydrolyzed into active form 5-(3-methyltriazen-1-yl) imidazole-4-carboxamide (MTIC).
Thereafter, MTIC is hydrolyzed to methyldiazonium ions (figure 2). Methyl group from
methyldiazonium ions are transferred to either guanine at N7 (60-80%) or O6 (5%) as well as
adenine at N3 (10-20%) site on negatively charged DNA which acts as a nucleophile[44, 45].
This process is called alkylation and it leads to substitution of thymine for cytosine
during DNA replication which results in multiple DNA adducts that have a high opportunity for
mismatched base pairing. Mismatched base pairs triggers mismatch base repair pathways which
aim to correct the damage but results in G2/M cell cycle arrest and eventually apoptosis[46, 47].
Research on O6-methylguanine-DNA methyltransferase (MGMT) deficient cells showed
that alkylation product O6-methylguanine (O6MeG) is the most powerful trigger for apoptosis
compared to N7-methylguanine and N3-methyladenine products[48]. Moreover, O6methylguanine lesions mediates antitumor activity of TMZ which requires functional DNA
mismatch repair (MMR) of tumor cell[49]. O6-methylguanine is mispairing with a thymine.
MMR machinery recognizes this. The mis-paired thymine is excised and replaces with another
thymine upon repair synthesis. This leads to an energy consuming cycle of DNA repair[50]. The
methylated guanine on the opposite strand cannot be repaired by MMR, hence, it persists leading
to replication fork arrest and eventual apoptosis[51, 52].
Research done in Maastricht University Medical Center between January 2005 and
January 2008 on effectiveness of temozolomide showed that temozolomide was an effective
chemotherapeutic drug for glioblastoma. The survival rate for groups with radiotherapy alone
was 8 months while the medial survival rate for patients who received TMZ and radiotherapy
was 12 months. The two-year survival rate was 4% for patients who used radiotherapy alone and
18% for patients who used TMZ and radiotherapy[53].
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TMZ efficacy is mainly limited by O6-methylguanine-DNA methyltransferase (MGMT).
DNA alkylation at O6 position of guanine leads to formation of crosslinks between adjacent
strands of DNA. Cross linking of adjacent double stranded DNA by alkylating agents is inhibited
by O6-methylguanine-DNA methyltransferase (MGMT) which rapidly reverse alkylation at O6
position of guanine. MGMT therefore plays a role in resistance to alkylating drugs[54, 55]
[56]. TMZ use may also lead to side effects such as severe nausea and vomiting, constipation,
diarrhea and loss of appetite[57].
Use of multi-target drugs such as combination drugs and hybrid drugs have shown to be
more advantageous. Hybrid drugs for instance target many points of the signaling network,
reduce the possibility of drug interaction occurrence, diminish the number of side effects and
adverse reactions as well as toxicity levels. In this research, we investigated if a hybrid
containing TMZ and nonsteroidal anti-inflammatory drugs (NSAIDs) target different signaling
networks and have a higher efficacy compared to TMZ and NSAIDs compounds?

NSAIDs
Tumor promoting inflammation is a cancer enabling factor. Often, tumors grow on sites
of chronic inflammation[58-60]. Virchow first linked cancer and inflammation in 19th
century[60]. However, the link was out of favor for a long time. There has been a growing
interest, a line of evidences[60-62] that substantiate the link and its now generally accepted that
cancer is linked to inflammation. This is why it has been added as an enabling factor in the
cancer hallmarks[10]. Noteworthy, inflammation mediators like chemokines, cytokines, tumor
growth factor, vascular endothelial growth factor (VEGF) and cyclooxygenase (COX) are also
upregulated in several cancer cases[63].
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Nonsteroidal anti-inflammatory drugs (NSAIDs) refers to drugs approved by Food and
Drug Administration (FDA) federal agency for use as anti-inflammatory, antipyretic and
analgesic agents[64]. Therefore, NSAIDs are used to reduce inflammation, treat muscle pain,
trauma cases, migraines etc [65, 66]. Research also shows that some NSAIDs are potential
anticancer agents.
The following is a list of NSAIDs that have shown anticancer properties; aspirin[67-69],
diclofenac[70-73], ibuprofen[74-76], ketoprofen, naproxen and oxaprozin.

Figure 3: Structires of NSAIDs used.
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Figure 4: Mechanism of action by non-steroidal anti-inflammatory drugs (NSAIDs). They inhibit
COX-1, COX-2 and NF-κB which are involved in activation of arachidonic acid. Arachidonic
acid is converted to prostaglandins and prostaglandins are responsible for inflammation, cell
proliferation, angiogenesis, invasion and metastasis. NF-Κb inhibits apoptosis but enhances
cell proliferation.

NSAIDs exert their anti-inflammatory effects by inhibiting an enzyme called
cyclooxygenase (COX). There are two COX isoforms, COX-1 and COX-2. COX-1 is common
in mammalian tissues but COX-2 is expressed quickly in response to pro-inflammatory
stimuli[77]. COX-2 is also often upregulated in cancers[77-79]. COX is an enzyme responsible
for converting arachidonic acid into prostaglandins (PGs). Prostaglandins are normally produced
in response to injury or infection and they cause inflammation which is associated with fever,
pain and swelling symptoms. PGs influence cancer angiogenesis, metastasis, apoptosis, and
invasion [80, 81]. Moreover, they are often highly expressed in cancer cells[82].
Experimental evidence has been mounting recently about influence of nuclear factorkappa B (NF-κB) on initiation, promotion and progression of cancer[83]. NF-κB is a
transcription factor involved in inflammatory, proliferation cell survival and immune responses.
It has 5 proteins RelA(p65), c-Rel, Rel B, p50, and p52 which dimerize and are held by NF-κB
11

inhibitors (IκBs) in the cytoplasm[83]. Cytokine-responsive IκB kinase -α (IKK-α) and IκB
kinase -β (IKK-β), are protein kinases whose function is needed for NF-κB activation by proinflammatory stimuli[84]. Research shows that NF-κB is activated in GBM/ astrocytes and
suppression of its activity can lead to up 90% suppression of tumor proliferation[85]. NSAIDs
have shown to inhibit/ suppress expression of NF-κB[86].
Interestingly, NF-κB is linked to COX in that the promoter region of the COX-2 gene
contains binding sites for NF-κB, which acts as a transcription factor to regulate the induction of
COX-2[87]. Since cancer has been linked to inflammation and inflammation is associated with
COX and NF-κB, NSAIDs use could be advantageous to cancer patients. This is why we
ventured into an examination of TMZ-NSAIDs imide hybrids as potential antiglioblastoma
agents. TMZ-NSAID compounds are imides. Research has shown that imides can act as
immunomodulatory anticancer drugs. Thalidomide analogues, for example, has been used to
treat several neoplasms[88]. There is a possibility that our imide hybrids may have
immunomodulatory properties in addition to antiglioblastoma properties of TMZ.

Anticancer Imides
Imides are organic compounds containing two acyl groups (figure 6) that are bound to a
nitrogen. According to the drug bank, there are more than 22 drugs that are imides. Among those
listed to have anticancer include lenalidomide used to treat multiple myeloma[89, 90], thalidomide
(figure 5) used to treat newly diagnosed multiple myeloma[91-93], amonafide (figure 5) which is
currently under investigation for treatment of breast, ovarian and prostate cancer[94, 95],
pomalidomide used to treat patients with multiple myeloma[96], LY-2090314 used to treat
pancreatic cancer and finally[97], glucoraphanin (figure 5) which is under investigation as an anticancer[98,99].
12

Figure 5: Structures of imides that have shown anticancer properties.

Imides seem to have different mechanism through which they inhibit progression of
tumors. Pthalimides have been studied and researched for their varied pharmacological effects.
They have shown anti-inflammatory, antimycobacterial, analgesic as well as anticonvulsant
properties. Actually, some of its derivatives like thalidomide have been used against multiple
myeloma, oral squamous cell carcinoma and prostate cancer[88]. Pthalimide-based curcumin
derivatives have shown anti-proliferative activity and anti-migrating activities. It inhibited
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anchorage-dependent activities as well as independent growth of prostate cancer cells. It was found
that it worked by altering expression of genes that are involved in cell proliferation [100]. Since
TMZ-NSAID hybrid are imides, there are chances that it could have anticancer properties
associated with imides for example anti-proliferation or anti-inflammatory and anti-angiogenesis.
To synthesize TMZ-NSAIDs hybrids, we considered the following synthetic methods:

Acylation of amides with activated forms of carboxylic acids
This is the most frequently used method to prepare imides. Acylation refers to the process
of adding an acyl group to a compound. Acylating agent is the compound that provides the acyl
group. An acyl group has a double bonded oxygen atom attached to an alkyl group. Usually, acyl
group is derived from carboxylic acids. An acyl group (figure 6) can be used to form carboxylic
acid, acid halides, acid anhydride, esters, amides, thioesters and acyl phosphates. Activated
forms of carboxylic acids like acid chlorides, methylarenes, potassium acyltrifluoroborates,
esters and anhydrides can be used in acylation of amides to form imides[101].

Figure 6: Acyl bonded to halogen

Figure 7:Acylation of amides with activated forms of carboxylic acids
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Mumm rearrangement
Mumm rearrangement was first discovered in 1910 and stands for intramolecular acyl
transfer [62]. It is an electrochemical four component reaction cascade and the last step is called
Mumm rearrangement. The rearrangement is an O - N‐acyl shift. It involves interactions between
an amine, an isonitrile, a carbonyl compound and a carboxylic acid[102]. Mumm rearrangement
process is very exothermic and can drive the entire process thermodynamically. Bronsted acids
mediates the acyl transfer[102].

Figure 8: Mumm rearrangement

Carbonylative cross-coupling of aryl halides

Carbonylation is a process that involves incorporation of CO into an organic molecule
like an alkene, alkenes, alcohol or existing C-X (X=I, H, Cl, Br) bond to form a carbonyl group.
This process is very important because it allows construction of new bonds as well as an
introduction of a carbonyl group.

Figure 9:Carbonylative cross-coupling of aryl halides

Carbonylative transformation takes place in presence of a metal catalyst. Some of the
transition metal catalysts which have been studied include palladium, ruthenium, rhodium and

15

manganese. Carbonylative synthesis of alkyl iodides and amides using manganese as a catalyst
have been used in synthesis of imides [102].

Figure 10:Manganese‐catalyzed carbonylative synthesis of imides from alkyl iodides

Oxidative decarboxylation of amino acids
Decarboxylation refers to a chemical reaction which removes a carboxyl group and
releases CO2. Oxidative decarboxylation is therefore a chemical reaction that leads to production
of carbon (iv) oxide and removal of a carbon group as a result of oxidation reaction.

N-Acyl amino acids can be converted to imides through oxidative decarboxylation. This
conversion takes place at room temperature, and it is induced by Ag+/Cu2+/S2O8 2- . The imide
yield through this process is pretty good, can be as high as 89%[102].

Figure 11:Oxidative decarboxylation of amino acids

Oxygenation of amides
Amides are primarily inert towards electrophilic oxidants. Manganese oxide has been
used in catalytic oxidation of amides to imides. Manganese oxide is thermally stable and it is
readily available in a number of oxidation states. Moreover, it is highly abundant. It has been
used in catalytic oxidation of quite a good number of reactions such as oxidation of alcohols to
aldehydes, alcohols to amides, hydrocarbons to alcohol, amines to imines and styrene to styrene
16

oxide. It can also be used in oxidation of amides into imides [102]. Copper (1) bromide and
Selectfluor combination have a very strong oxidation ability. It has been used in oxidizing
amides into imides. The oxidation process takes place at room temperature in acetonitrile and is
complete in less than an hour [102].

Figure 12:Copper mediated oxidation of amides to imides
by selectflour (https://www.sciencedirect.com/science/article/abs/pii/S0040403911002826)

Figure 13:Oxidation of amides to imides

In this research, we attempted synthesis of TMZ-NSAIDs imide hybrids using
“acylation of amides with carboxylic acid derivatives” method to synthesize TMZ-NSAID
compounds. This is because NSAIDs have a carboxylic acid functional group and temozolomide
has an amide group. However, we did not successfully synthesize the hybrid even after many
trials. This prompted us to synthesize hybrids of diclofenac and purines using acylation method.
Our choice of diclofenac was influenced by the results observed while testing LC50 values of
selected NSAIDs. Diclofenac changed U87 MG cell motility and had the lowest LC50 value. We
chose purines because research shows they can enhance TMZ antitumor efficacy. Fortunately,
we were successful in synthesizing novel hybrids of diclofenac and purines.
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Purines

Purine is a six-membered and a five-membered nitrogen-containing ring (figure 14). It is
used by cells to make DNA and RNA building blocks[103].
Examples of purines are Guanine and Adenine. Rapidly
proliferating cells demand purines, which are basic
biochemical compounds, in large quantities for nucleotide
synthesis as well as DNA replication. Moreover, purines are

Figure 14: Purine structure

known to be sources of energy that drive cellular biological
processes, are involved in host-tumor interaction and modulate immune cell responses. This is
why they are upregulated in tumor microenvironment[104, 105].

One of the characteristics of tumors is, they proliferate rapidly[106]. Targeting this
characteristic has been exploited in the past in development of anticancer drugs. These drugs
either alter or inhibit DNA synthesis. Generally, a mature human being has few cells replicating.
However, some cells are continually replicating e.g cells in the bone marrow, hair follicles and
gastrointestinal lining. This means that targeting DNA replication may result in high levels of
toxicity thus limiting the amount of drug that can be tolerated by a patient. Despite the toxicity
levels, effective drugs targeting DNA replication have been developed in the past and they
actually increased survival rates and even cured patients [107].
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Interestingly, purine analogues have been used since 1953 against cancer. Purine
analogues refers to compounds which have a structure similar to that of purines but they have a
different mechanism of action, metabolism, pharmacokinetics and adverse conditions. They are
considered as antimetabolites, that is, they compete or interfere with nucleoside triphosphates in
the synthesis of DNA and RNA. These compounds have been used against leukemia and
lymphomas[108, 109]. 6-mercaptopurine was approved by FDA in 1953 for treatment of
leukemia in children. It is curative and currently
considered the standard treatment for the cancer.
Thioguanine was then approved in 1966 and has been
used in treatment of chronic myeloid leukemia, acute
myeloid leukemia and acute lymphocytic leukemia[110].
Other purine analogues that have been approved since

Figure 15: Structure of 6mercaptopurine

then include fludarabine, cladribine, pentostatin,
azathioprine, clofarabine, nelarabine, thioguanine and pentostatin [107, 111]. In this research,
we have investigated aminopurines (figure 16) including guanine, adenine, 2-chloro-7H-purine-
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6-amine, 2-fluoro-7H-purine-6-amine, 2-amino-6-chloropurine amines and p-anisidine.

Figure 16: Structures of purines used
Mechanism of action
Nucleoside analogues diffuse into cells with the aid of membrane transporter. Once in the
cell, they are converted into analogues of cellular nucleotides by enzymes[112]. Polymerases
then incorporate the analogues into the DNA during normal DNA synthesis. They can also be
incorporated into DNA during DNA excision repair synthesis. Thereafter, these analogs
compromise the integrity of DNA structure or inhibit one or more enzymes that are critical for
DNA synthesis. This leads to stalling of replication forks as well as chain termination. Molecular
mechanisms can sense when there is a stalling in the replication process and activate cell cycle
checkpoints as well as DNA repair processes. Other DNA damage sensors include ataxia
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telangiectasia and Rad3-related protein (ATR) ataxia-telangiectasia mutated (ATM) and DNAdependent protein kinase (DNA-PK). DNA repair processes are to a large extent responsible for
drug resistance. Apoptosis is initiated when DNA repair processes fail to repair the DNA or
when the stalled forks are not stabilized[107, 113, 114].

Purine association with GBM
Research shows that purine nucleotides increases the toxicity of TMZ when
combined[115]. Additionally, purine synthesis has been linked to the highly aggressive nature of
GBM[116]. Also, it has been observed that there is an elevated expression in purine synthetic
enzymes whenever there is a poor prognosis in GBM patients[117]. Moreover, high rates of
purine synthesis in tumorigenic cells increase their ability to repair DNA damaged cells hence
leading to tumor recurrence. Even DNA damage caused during GBM radiation therapy is
repaired when purine synthesis is upregulated. This leads to tumor recurrence and therapy
resistance[117-119].
Noteworthy, de novo purine synthesis can generate adenosine triphosphate (ATP) and
guanosine triphosphate (GTP). ATP is a nucleoside triphosphate that is made up of three
components; adenine, sugar ribose and a triphosphate. On the other hand, GTP is made up of;
guanine, sugar ribose and triphosphate. ATP and GTP act as sources of energy or activators of
substrates in metabolic reactions. They are also molecular precursors of DNA & RNA. In GBM,
de novo GTP synthesis is upregulated and de novo ATP synthesis is active in both normal brain
tissues and GBM but not upregulated. Upregulation of GTP synthesis enhances GBM
proliferation. Inhibiting de novo GTP synthesis overcomes resistance to GBM radiation
therapy[118] [120].
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Blood Brain Barrier
Glioblastoma is a brain tumor. All orally administered anti-glioblastoma drugs have to
pass through blood brain barrier (BBB). BBB is a membrane barrier found between the blood
vessels of the brain and the rest of the cellular brain tissue. It is selectively permeable in that it is
responsible for regulating the passage of molecules into the brain neuronal environment[121]. It
was discovered by Paul Ehrlich a German physician in the later part of the 19th century[122].
The BBB function is enabled by its various components. The key structure to the function of the
BBB is the endothelial cells that line the inner part of the brain blood vessels. The endothelial
cells are closely adhering to each other thus forming the functional tight junctions which thus
allows specific molecules to pass through to the brain tissue [123]. Some of these molecules are
mainly fat soluble or smaller molecules. Other large molecules can also pass through with the aid
of protein transporters. These include glucose, amino acids, nucleotides and ions[124].
Astrocytes are another group of cells that make up the blood brain barrier. These star
shaped cells form feet like projections that surround the endothelial cells of BBB[125]. Their
role is mainly to provide support to the endothelial cells and providing nutrients to the tissues.
Astrocytes also facilitate repair and fluid regulation via the aquaporin 4 water channel[126].
Neurons also form the BBB. They are closer to the blood vessels and the astrocytes, and
this closeness makes them sensitive to the changes in the ion balance. Neurons are also
responsible for blood flow regulation and controlling permeability.
Pericytes are another group of cells found on the endothelial cells surface and are
attached to it by gap junctions. They have a major role in stabilizing the endothelial cells by
developing tight junctions and depositing the extracellular matrix[127].
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The BBB action is mainly to offer protection to the brain from external pathogens that are
restricted from getting to the brain tissue. Antibodies are large to penetrate the BBB to offer
immunity to the brain tissues and thus this is the main protective mechanism of the brain.
Majority of the drugs cannot pass through the BBB due to the selective permeability thus making
it difficult to treat many neurological diseases. The BBB becomes permeable during
inflammation after infections such as Toxoplasmosis and meningitis and this allows bacteria and
viruses to gain access to the BBB[128]. Apart from protecting the brain from pathogens, the
BBB also allows passage of essential nutrients to the brain such as glucose through the various
transporter proteins[128].
Indeed, it is paramount to find out if a drug can pass through the BBB to reach its target
site. In this research, I used molinspiration software to predict the permeability of hybrid
compounds, TMZ and NSAIDs and determined whether they can pass through the BBB.

Lipophilicity
Another important factor worth predicting before drug synthesis is lipophilicity.
Lipophilicity is a Greek word which means “fat friendly”. It is used to refer to the solubility of
compounds in fats, lipids, oils and non-polar compounds e.g toluene and hexane. As a
physiochemical parameter, lipophilicity plays a role in absorption, distribution, metabolism,
excretion and toxicity (ADMET) of a drug. This therefore means lipophilicity of a drug influence
its potency and selectivity. When lipophilicity is too high, then the drug will lead to toxicity and
metabolic clearance hence low potency. When it is too low, it leads to low potency too[129].
Lipophilicity of a compound is measured as a partition coefficient. Partition coefficient
refers to the ratio of the sum total of all compounds in two phases. The most common method of
measuring lipophilicity is called “shake flask method”. In this method, a sample or a compound
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is dissolved in a mixture of water and octanol then the mixture is shaken and agitated until an
equilibrium is reached. The two phases, octanol and water, are then separated. Octanol-water
partition coefficient (Log P) can then be calculated. Optimal range of lipophilicity is between 0
and 4[129, 130].

Oral Bioavailability
Oral bioavailability is also a physiochemical parameter that’s important to consider
before synthesizing drugs. Oral bioavailability refers to the ratio between the amount of drug
administered orally and the amount that reaches systemic circulation. Unlike drugs administered
intravenously that are fully available in the bloodstream upon injection, orally administered
drugs must pass through many barriers before reaching the target point of action.
High levels of oral bioavailability reduce the quantity of drug administered. Lower
quantities of drug lead to reduced toxicity and relatively reduced side effects. On the other hand,
low oral availability levels lower drug efficacy[131].
In 2005, Lepinski’s rule of 5 was formulated in order to set guidelines for measuring oral
bioavailability of drugs. According to this rule, poor oral bioavailability is likely when there are
more than 5 hydrogen bond donors, 10 hydrogen bond acceptors, the molecular weight (MW) is
greater than 500, and the calculated Log P (CLog P) is greater than 5. Lipinski also stated that
this rule would only hold for compounds that were not substrates for active transporters[132,
133].
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CHAPTER 2

MATERIALS AND METHODS
Drawing of Chemical Structures
To draw structures of different compounds and hybrids, Chemdraw online software,
(https://chemdrawdirect.perkinelmer.cloud/js/sample/index.html), Reaxys structure editor
(https://www.reaxys.com/#/structure-editor ) and Marvin Sketch online software was used.
Figures were illustrated using BioRender software, canva software and Adobe software.

Calculation of Molecular Properties
To determine if the temozolomide, NSAIDs and hybrids could pass through the blood
brain barrier, we used Molinspiration software to calculate molecular properties.

Chemistry
Reagents and solvents used to synthesize and analyze the products were bought from
Sigma-Aldrich company. All the experiments were done in a conventional fume chamber.
Flasks, beakers, magnetic stirrer, separating funnel, stir bar and rotavapor were supplied by the
Andrews University Chemistry department and Dr Desmond Murray’s lab. IR spectra was
obtained using Thermo Scientific Nicolet iS50 ATR Infrared Spectroscopy.
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Experimental procedures for imide and amide synthesis

Figure 17:Chemical equation for imide synthesis from 4-methoxybenzamide and aspirin
Below is a general procedure representing the trials done using aspirin as the carboxylic
acid and 4-methoxybenzamide and TMZ as the amides. The procedures were done in different
variations e.g different times of refluxing or only stirring the mixtures.
An oven dried 50 ml round bottom flask containing a stir bar was clamped on top of a
magnetic stirrer. 25 ml of dry dichloromethane was then added into the flask before attaching a
drying tube and stirring gently. Thereafter, the following reagents were added; (1) 0.002 mol
carboxylic acid, (2) 0.0025 mol oxalyl chloride and (3) 10 drops of dry dimethylformamide
(DMF). The drying tube was then removed and a water-cooled condenser was attached. The
mixture was refluxed with continued stirring for 45 minutes to produce acyl chloride. After 45
minutes of reflux, the condenser was replaced with a drying tube then the mixture was dried in
an ice-bath for 5 minutes. 0.002 mol potassium carbonate was then added into the cooled mixture
and stirred for 10 minutes. The following reagents were then added into the mixture; add (a)
0.002 mol of amide and (b) 0.002 mol diisopropylethylamine. The mixture was then stirred using
a magnet stirrer at room temperature for 24 hours. Thereafter, the reaction mixture was poured
into a 250 ml beaker containing ice and 30 ml 1M HCl. The mixture was then stirred for 15
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minutes. The mixture was then extracted three times with ethyl acetate. The combined organic
layers were then dried using anhydrous sodium sulphate then filtered into a round bottom flask
and rotovated. The product was weighed and analyzed using IR and NMR. IR and NMR spectra
of the starting compounds and product was then compared.
Below is an amide synthesis procedure that was used to synthesize novel hybrids of
diclofenac and purines.
An oven-dried 50 ml round bottom flask containing a stir bar was clamped on top of a
magnetic stirrer. 25 ml of dry dichloroethane was then added into the flask before attaching a
drying tube and stirring gently. The following reagents were then measured out and added into
the flask: (1) 0.002 mol diclofenac, (2) 0.0025 mol oxalyl chloride and (3) 10 drops of dry
dimethylformamide (DMF). Drying tube was then removed and a water-cooled condenser was
attached to the flask. The mixture was then refluxed with continued stirring for 1 hour to produce
the acyl chloride. The condenser was replaced with a drying tube then the mixture was allowed
to cool in an ice-bath for 5 minutes. 0.002 mol potassium carbonate was then added to the
mixture and stirred for 10 minutes. The following reagents were measured out and added into the
flask (a) 0.002 mol purine and (b) 0.002 mol diisopropylethylamine. Thereafter, the mixture was
stirred for 4 hours. Slowly, the reaction mixture was poured into a 250 ml beaker containing ice
and 10 ml 1M HCl and 20ml saturated NH4Cl. Stirring continued for 15 minutes before
extracting the mixture three times with ethyl acetate. Combined organic layers were dried with
anhydrous sodium sulphate then filtered into a round bottom flask. A rotavapor was used to
gently remove the solvent. IR of the product was then taken and compared with IR of the organic
starting materials. Finally, the actual yield and % yield of the product was determined.
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Figure 18: Chemical equations for the amides synthesized. JRP1, JRP2, JRP3, JRP4, JRP5,
JRP6 represent hybrid compounds synthesized.
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Biology
Once novel hybrids had been synthesized, I tested their LC50 and observed changes in
morphology. These tests were done on U87MG cell line in Dr. Denise’s lab at the Biology
department, Andrews University. Below are procedures, activities and methods done in the lab.

Maintaining of U87MG Cells
U87MG Glioblastoma cells were grown in standard tissue 100 mm or 60 mm culture
dishes. They were then allowed to grow in 8 ml or 3 ml respectively of MEM (Minimal Essential
Media; Invitrogen) that was supplemented with 100U/ml penicillin, streptomycin and 10% fetal
bovine serum (FBS). The cells were then kept in a humidified incubator with Carbon dioxide
concentrations of 5 % and a temperature of 37 °C.
The media was changed three times every week. Whenever the cells covered more than
80% of the tissue culture dishes, the media was removed followed by addition of 2ml for 100
mm dishes 1ml for 60 mm dishes of 1X TE (trypsin EDTA; Invitrogen). Trypsin was used to
detach the cells from the dish. Half of the cells floating in trypsin were then removed. 8ml or
3ml, respectively of new media was then added before incubation of the cells.

Determination of LC50 lethal concentration
Determination of LC50 was a process that took 72 hours. The first step was transferring
10,000 U87 MG cells into each well in the 12 well plate followed by treating the cells with drug,
fixing, staining, and counting.
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Transferring 10,000 U87 MG cells
90 μl of trypan blue was transferred into a microcentrifuge tube. Old media was then
removed from the dish before adding 2 ml or 1 ml respectively of trypsin. Trypsin was used to
wash the cells off the dish. Thereafter, 10 μl of cells suspended were transferred into the
microcentrifuge tube containing 90 μl of trypan blue. Mixing of the cells and trypan blue was
done using a pipette. Immediately after, 10μl of the mixture was introduced into the
hemocytometer via capillary action. The number of cells was determined then diluted to create
10,000 cells for each well of a 12-well plate. 1ml of media containing 10,000 cells was
introduced into each well of the 12-well plate. The cells were then incubated in a humidified
incubator with Carbon dioxide concentrations of 5 % and a temperature of 37 °C for 24 hours to
allow them to attach to the plate.
Treating U87 MG cells with drugs
0.02 g of compound was first dissolved in 1 mL of dimethyl sulfoxide (DMSO) to create
a stock solution. As long as we kept the DMSO concentration below 1%, cells behaved and grew
normally with no additional cell death. Eleven serial dilutions of half concentration in MEM
media were created starting at 2mg/ml. The final well contained media only. After treating the
cells with the drug, they were incubated again in a humidified incubator with Carbon dioxide
concentrations of 5 % and a temperature of 37 °C for another 24 hours.
Cell viability count
First, the media was removed then 1 mL of methanol was added into each well and
incubated for 5 minutes to fix the cells. Methanol was then removed before adding 1 mL of
crystal violet stain. Incubation for another 5 minutes then followed. Thereafter, crystal violet was
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carefully removed using a pipette. Excess stain was removed with repeated washing in water.
The wells were then allowed to dry for another 24 hours.
Using a sharpie, three dots were randomly marked under the well. An inverted light
microscope at 400X and Clay Adams Laboratory Counter was used to count the number of cells
in the field of view for the three dots. An average was then calculated before determining the
total number of cells in each well.

Compounds screened
The following are the compounds and mixtures screened; TMZ, aspirin, diclofenac,
ibuprofen, naproxen, oxaprozin and ketoprufen. 1:1 and 2:1 ratio of TMZ and aspirin, TMZ and
diclofenac, TMZ and oxaprozin as well as TMZ and ketoprufen were also screened. The
following purines and their hybrids with diclofenac were also screened: guanine, adenine, 2chloro-7H-purine-6-amine, 2-fluoro-7H-purine-6-amine, 2-amino-6-chloropurine p-anisidine.
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CHAPTER 3

RESULTS

Computational predictions for TMZ, NSAIDs, purines and novel hybrid compounds.
Molinspiration online software was used to calculate molecular properties of TMZ,
NSAIDs, purines and novel hybrid compounds (table 2). Drug potency depends on chemical and
physical properties of the drug. Drugs must be transported and distributed in a complex
multicompartment biological system to site of action and should be complementary to a
structurally unknown receptor. Lipophilicity plays a role in this process. The term lipophilicity
which means ‘friendly’ in Greek, refers to the ability of a compound to dissolve in oils, fats,
lipids as well as non-polar compounds[129, 134]. Therefore, it contributes to absorption,
distribution, metabolism, elimination and toxicity (ADMET) properties of a drug. Most of the
drugs synthesized and tested have lipophilicity (LogP) value within the optimal range of 1-5.
TMZ had the lowest LogP value of -1.9 while a novel hybrid of p-anisidine and diclofenac had
the highest LogP value of 6.18. Diclofenac has a LogP value of 4.57. All the hybrids with
diclofenac compound had a LogP value higher than 4.57 except hybrid of diclofenac and TMZ
which has a LogP of 2.80 and hybrid of diclofenac and guanine which has a LogP value of 4.20.

Lipinski rule of 5 states that poor oral bioavailability is likely when there are more than 5
hydrogen bond donors, 10 hydrogen bond acceptors, the molecular weight (MW) is greater than
500, and the calculated Log P (CLog P) is greater than 5. Only TMZ, guanine and hybrid of
TMZ and aspirin have a negative LogP value. On the other hand, only a hybrid of p-anisidine
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and diclofenac had a LogP value greater than 5. All the other compounds had a value within or
very close to the range of 1-5 LogP value. All the compounds tested had less than 5 hydrogen
bond donors(nOHNH), 10 or less than 10 hydrogen bond acceptors and molecular weight of less
than 500 (table 2).
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Table 2: Predicted blood-brain barrier permeability and Bioavailability of TMZ, NSAIDs, purines and novel hybrid
compounds. LogP – Octanol-water partition coefficient, TPSA – Topical polar surface area, nAtoms – Number of atoms, nON –
Number of hydrogen-bond accepted, nOHNH – Number of hydrogen bond donors, MW – molecular weight, nRotB – Number of
rotatable bonds

Compound

LogP

TPSA

nAtoms

nON

nOHNH

MW

nRotB

Volume

Lepinski rule

TMZ

-1.9

108.19

14

8

2

194.15

1

152.12

pass

Aspirin

1.43

63.60

13

4

1

180.16

3

155.57

pass

Diclofenac

4.57

49.33

19

3

2

296.15

4

238.73

pass

Ibuprofen

3.46

37.30

15

2

1

206.28

4

211.19

pass

Naproxen

3.38

46.53

17

3

1

230.26

3

213.97

pass
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Oxaprozin

3.75

63.33

22

4

1

264.88

5

264.88

pass

Ketoprofen

3.59

54.37

19

3

1

254.28

4

234.83

pass

p-anisidine

1.07

35.26

9

2

2

123.16

1

120.88

Pass

Guanine

-0.93

100.46

11

6

4

151.13

0

119.97

Pass

Adenine

0.23

80.49

10

5

3

135.13

0

111.84

Pass

2-Chloro-7H-purine-6-amine

1.23

80.49

11

5

3

169.57

0

125.38

Pass

2-Fluoro-7H-purine-6-amine

0.72

80.49

11

5

3

153.12

0

116.77

Pass

2-amino-6-chloropurine

0.43

80.49

11

5

3

169.57

0

125.38

Pass

p-anisidine + diclofenac

6.18

50.36

27

4

2

401.29

6

340.07
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Guanine + diclofenac

4.20

115.56

29

8

4

429.27

5

339.16

Pass

Adenine + diclofenac

4.94

95.59

28

7

3

413.03

5

331.03

Pass

2-Chloro-7H-purine-6-amine 5.94

95.59

29

7

3

447.71

3

344.57

Pass

95.59

29

7

3

431.26

5

335.96

Pass

95.59

29

7

3

447.71

5

344.57

Pass

+ diclofenac

2-Fluoro-7H-purine-6-amine 5.42
+ diclofenac

2-amino-6-chloropurine +

5.55

diclofenac
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IR Spectroscopy Analysis
Novel hybrid compounds were synthesized in the Chemistry department. IR spectroscopy
was done to confirm that the desired compounds were synthesized. The product was also
weighed to find out the percentage yield of the product.
Imide N-H stretch, which falls between 3150 and 3250 was not present in all products.
This means that imides were not successfully synthesized (table 3). O-H carboxylic acid band at
2800-3500 cm-1 was expected in aspirin’s IR spectra. This peak was observed at 2830 cm-1. The
N-H amide peak expected between 3100 - 3500 cm-1 was observed at 3158 cm-1. TMZ doublet
N-H peaks were also observed at 3328 and 3421 cm-1. Diclofenac had a peak at 3321 cm-1. We
expected two peaks for primary amines (N-H) within the range of 3000 and 3300 cm-1 range. All
the primary amines had these two peaks. All the products synthesized had an amide (C=O) peak
within the expected range (table 4).
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Table 3: Diagnostic IR peaks for TMZ and 4 methoxybenzamide (amides), aspirin (carboxylic
acid) and diagnostic peaks for hybrids of aspirin and 4-methoxybenzamide and hybrid of aspirin
and TMZ are missing
Compound
TMZ
4-methoxybenzamide
Aspirin
4-methoxybenzamide + aspirin
TMZ + aspirin

Diagnostic Peaks
3328 (amide) 3421
(amide)
3158 (amide)
2830 (Carboxylic acid)

Results
NA (Not Applicable)
NA
NA
Imide peak not observed
Imide peak not observed

Table 4: Diagnostic IR peaks for carboxylic acid(diclofenac), amino purines (guanine, adenine,
2-Chloro-7H-purine-6-amine, 2-Fluoro-7H-purine-6-amine, 2-amino-6-chloropurine) amines (
p-anisidine) and amides (hybrid of 2-amino-6-chloropurine + Diclofenac, 2-Chloro-7H-purine6-amine + Diclofenac, Adenine + Diclofenac, Guanine + Diclofenac, P-Anisidine + Diclofenac
and 2-Fluoro-7H-purin-6-amine + Diclofenac) analyzed
Compound

Diagnostic peaks

Diclofenac

3321 (carboxylic acid)

2-Chloro-7H-purine-6-amine

3274 (amine) 3125 (amine)

2-Fluoro-7H-purine-6-amine

3289 (amine) 3117 (amine)

2-Amino-6-chloropurine

3297 (amine) 3127 (amine)

p-anisidine

3219 (amine) 3006 (amine)

Guanine

3314 (amine) 3110 (amine)

Adenine

3286 (amine) 3103 (amine)

2-amino-6-chloropurine + Diclofenac

1675 (amide)

2-Chloro-7H-purine-6-amine +
Diclofenac

1673 (amide)

Adenine + Diclofenac

1672 (amide)

Guanine + Diclofenac

1663 (amide)

p-Anisidine + Diclofenac
2-Fluoro-7H-purin-6-amine +
Diclofenac

1664 (amide)
1663 (amide)
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Table 5 below shows detailed structures and their product yield. Product yield ranged
between 54% and 133%. Hybrid of 2-amino-6-chloropurine and diclofenac had the lowest yield
of 54% followed by hybrid of 2-Fluoro-7H-purine-6-amine and diclofenac with a 61% yield.
Hybrid of adenine and diclofenac had a % yield of 68 while a hybrid of guanine and diclofenac
had a % yield of 70. Percentage yield of novel hybrid of p-anisidine and diclofenac was
relatively high at 86% and product yield of novel hybrid of 2-chloro-7H-purine-6-amine and
diclofenac was the highest at 133%. Novel hybrid of 2-chloro-7H-purine-6-amine and diclofenac
most likely had impurities from solvents or catalysts hence the product yield higher than 100%.
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Table 5: Reactants and products structures
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Biology
LC50 Values
LC50 values ranged from 0.0056 to 0.2021. Two NSAIDs had an LC50 lower than that of
TMZ. These compounds include diclofenac which had the lowest LC50 of 0.0139 and oxaproxin
with 0.0455. TMZ had LC50 of 0.059. All 1:1 mixture of TMZ and NSAIDs had a lower LC50
compared to LC50 of the individual compounds except in case of mixture between ketoprofen
and TMZ (figure 19).

LC50
0.25

Concentration mg/ml

0.2

0.15

0.1

0.05

0

Compound
Compound

Mixture

Figure 19:Comparison between LC50 of individual compounds and LC50 of 1:1 mixtures of the
compound and TMZ
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In the case of TMZ: NSAIDs 2:1 mixture, LC50 values changed to a value closer to that
of TMZ’s LC50. The table below illustrates these findings (figure 20).

LC50
0.25

Concentration mg/ml

0.2

0.15

0.1

0.05

0

Compound
Compound

Mixture

Figure 20: Comparison between LC50 of individual compounds and LC50 of 1:2 mixture of the
compound and TMZ respectively.
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Novel hybrid compounds had LC50 values ranging from 0.0056 and 0.0247. Only novel
hybrid of p-anisidine and diclofenac had LC50 value higher than that of diclofenac. Generally, the
hybrids had lower LC50 values compared to LC50 values of individual compounds (figure 21).

Concentration mg/ml

LC50
0.5
0.45
0.4
0.35
0.3
0.25
0.2
0.15
0.1
0.05
0

Compound
Compound

Mixture

Figure 21: Comparison between LC50 of individual compounds and LC50 of novel hybrids of
purines and diclofenac
Figure 22 below shows effect of TMZ, NSAIDs, amino purines, p-anisidine and novel
hybrids of diclofenac and purines on U-87MG glioblastoma cell viability compared to untreated
U-87MG cells. Red arrows indicate the LC50 values of each compound. Error bars indicate
standard error, n = 3 independent experiments in triplicate.
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45

46

47

48

Figure 22: The effects of TMZ. NSAIDs, purines and novel hybridsl on U-87MG glioblastoma
cells compared to untreated U-87MG cells. Red arrow indicates the LC50 value. Error bars
indicate standard error, n=3 independent experiments in triplicate.

Interesting morphological observations were observed in cells treated with diclofenac,
adenine and 2-amino-6-chloropurine. In the case of diclofenac, it was observed that at high
concentrations, cells divided and remained localized or close to parent cell. This suggests that
diclofenac influences cell motility. Moreover, it was observed that the number of cell clusters
increased with decreasing concentration and eventually there were no clusters at low
concentrations. Cell shape was observed to be more of an irregular circle and not star shaped as
in the case of normal U-87MG glioblastoma cells.
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Figure 23:Morphological observations on diclofenac. A. A picture showing field of view on a Leica DMIL type
090-135.001 inverted microscope. Red cycles show cluster of U87MG GBM cells treated for 24 hours with
0.03125 mg/ml of diclofenac and stained with crystal violet. B. picture showing field of view on a Leica DMIL
type 090-135.001 inverted microscope. Red cycles show cluster of U87MG GBM cells treated for 24 hours
with 0.01562 mg/ml of diclofenac and stained with crystal violet. C. A picture showing field of view on a Leica
DMIL type 090-135.001 inverted microscope. On the image are U87MG GBM cells not treated with diclofenac
and stained with crystal violet (control).
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CHAPTER 4

DISCUSSION
Lipophilicity
Lipophilicity is a Greek word that means “fat friendly” or “fat loving”. It is often referred
to as LogP. LogP represents the ratio at equilibrium of the concentration of a compound between
two phases, an oil and a liquid phase. It is a physiochemical parameter that predicts how soluble
a compound is in fats, lipids, oils and non-polar compounds. Therefore, it plays a role in
absorption, distribution, metabolism, excretion and toxicity of a drug [88][134]. When
lipophilicity is high, i.e. greater than 5, it results in high metabolic turn over, poor oral absorption
and low solubility. There is also a risk of increased toxicity associated with high lipophilicity.
Low lipophilicity, i.e. below 1, leads to low efficacy of the drug since it negatively impacts
permeability and drug potency. Study shows that optimal logP is between 1 and 4[135]. The
compounds synthesized have LogP values within the range of 1-5 or close except the novel
hybrid compound of diclofenac and p-anisidine which has a logP value of 6.18. The high logP
values may be attributed to the high logP value of diclofenac which is 4.57. A hybrid of
diclofenac and other compounds with optimal logP values generally have higher logP values.
Temozolomide has a low logP value of -1.9. This low lipophilicity may not be a problem since
TMZ is a prodrug, that is, it does not require metabolic activation and it is converted to active
compound spontaneously at blood pH[52, 136]. Prior research shows that TMZ has100%
bioavailability when taken orally and can pass through the BBB. This is attributed to its small
size and lipophilic properties [137].

51

Oral Bioavailability
As stated earlier, oral bioavailability refers to the ratio between the amount of drug
administered orally and the amount that reached the systemic circulation. Oral drugs pass
through many barriers before reaching target point of action. Drugs with high level of oral
bioavailability are given in low quantities, which leads to reduced toxicity as well as side effects.
On the other hand, drugs with low oral bioavailability have lower drug efficacy[131]. Lipinski’s
rule formulated in 2005 sets the guidelines for measuring oral bioavailability. According to this
rule, poor oral bioavailability is likely when there are more than 5 hydrogen bond donors, 10
hydrogen bond acceptors, the molecular weight (MW) is greater than 500, and the calculated Log
P (CLog P) is greater than 5. All the compounds tested had less than 5 hydrogen bond
donors(nOHNH), 10 or less than 10 hydrogen bond acceptors and molecular weight of less than
500. Only a novel hybrid of p-anisidine and diclofenac had Log P value of 6. Therefore, all the
compounds except the hybrid of p-anisidine and diclofenac passed the Lipinski’s rule.

Blood Brain Barrier
Drugs pass the blood brain barrier mainly through transmembrane diffusion. There are
factors that influence the ability of substances to cross the blood brain barrier. Lipophilicity and
molecular weight are two of the main factors. Generally, molecules with low molecular weight
of not more than 500 and high lipophilicity can cross the blood brain barrier. When lipophilicity
is too high for instance more than LogP value of 5, it results in low solubility, high toxicity, poor
oral absorption and high metabolic turnover. Low lipophilicity leads to reduced efficacy and
poor bioavailability. Drugs that pass the Lipinski’s rule of 5 are more likely to pass the blood
brain barrier as well. Therefore, all the compounds tested except the novel hybrid of diclofenac
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and p-anisidine may pass the blood brain barrier. This is in congruence with prior research which
showed that TMZ, aspirin, diclofenac, ibuprofen, naproxen, ketoprofen can pass through BBB
[138-142]. Purines can pass through BBB via carrier proteins[143, 144].

Chemistry
Synthesis of TMZ-NSAIDs imides
There are various synthetic methods for synthesizing imides. They include acylation of
amides with carboxylic acid derivatives, Mumm rearrangement of isoimides, oxidative
decarboxylation of amino acids, oxygenation of amides and carbonylative coupling of aryl
halides[102]. Based on the nature of our compounds, acylation of amides with carboxylic acid
derivatives was the most feasible synthetic method. Acylation refers to the process of adding an
acyl group to a compound. NSAIDs are carboxylic acids. Acyl group is therefore derived from
the NSAIDs. The first step in our procedure involved a reaction between carboxylic acid
(NSAIDs) and oxalyl chloride in presence of dimethylformamide (DMF). DMF acted as a
catalyst and oxalyl chloride or thionyl chloride reacted with carboxylic acid to form acyl
chloride.

Figure 24: Conversion of a carboxylic acid to acyl chloride using
oxalyl chloride and a DMF catalyst
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Figure 25: Conversion of a carboxylic acid to acyl chloride using
thionyl chloride

Below is a mechanism for conversion of carboxylic acids to acid chlorides using thionyl
chloride.

1.

Nucleophilic attack on Thionyl Chloride

2.

Removal of Cl leaving group

3.

Nucleophilic attack on carbonyl
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4.

Removal of leaving group

5.

Deprotonation

Figure 26: mechanism for conversion of carboxylic acids to acid chlorides using thionyl
chloride.
Activated forms of carboxylic acids, like acid chlorides in our case, can be used in
acylation of amides to form imides. Therefore, the second part of the reaction involved a reaction
between acid chloride and TMZ (amide).

Figure 27:Acylation of amides with acid halides to form imides.
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Ethyl acetate was used to extract the product (imide). Unfortunately, NMR and IR result
showed that the imide was not successfully synthesized. More trials were done with different
variations but none has been absolutely successful. Noteworthy, the first step that involved
conversion of carboxylic acid to acid chloride was successful.

Synthesis of diclofenac-purine hybrids
Six amides were synthesized through a reaction between diclofenac and each of six
amines which included p-anisidine, guanine, adenine, 2-chloro-7H-purine-6-amine, 2-fluoro-7Hpurine-6-amine and 2-amino-6-chloropurine. The first step of this process was the conversion of
diclofenac which is a carboxylic acid to acid chloride. DMF was used as a catalyst in the process.

Figure 28: Conversion of a carboxylic acid to acyl chloride using
oxalyl chloride and a DMF catalyst

The resultant acyl chloride was reacted with an amine to form the amide product.

Figure 29: Acyl chloride reaction with amine to form amide
Below is a reaction mechanism for this step.
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1.

Nucleophilic attack by the amine

2.

Removal of leaving group

3.

Deprotonation

Figure 30: Reaction mechanism for reaction of acyl chloride with amine
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IR spectroscopy
Infrared spectroscopy (IR) is a measure of interactions of infrared radiation and matter. It
is often used in analysis of chemical compounds to identify functional groups. In this research,
amide and carboxylic acids were reacted with a goal to have a hybrid which is an imide. Amides
used included 4-methoxybenzamide and TMZ. Aspirin was used as carboxylic acid. Imide N-H
stretch, which falls between 3150 and 3250 was not present in all products. O-H carboxylic acid
band at 3000–2500 cm-1 was expected in aspirin’s IR spectra. This peak was observed at 2830
cm-1. The N-H amide peak expected between 3100 - 3500 cm-1 was observed at 3158 cm-1. TMZ
doublet N-H peaks were also observed at 3328 and 3421 cm-1.
In the second part of this research, diclofenac, a carboxylic acid, was reacted with
purines which are primary amines to form novel hybrids which are amides. Carboxylic (O-H)
peak was expected between 2800-3500 cm-1 range. Diclofenac had a peak at 3321 cm-1. We
expected two peaks for primary amines (N-H) within the range of 3000 and 3300 cm-1 range. All
the primary amines had these two peaks. The product would therefore not have either the
carboxylic acid peak or the primary amine peaks but have amide peak which was expected at
1630-1690 cm-1 range. All the products synthesized had an amide (C=O) peak within the
expected range.

Biology
As mentioned earlier, GBM is the most common, most lethal and most aggressive
primary malignant brain tumor[145]. It has a very low median survival rate of 15 months only
and often poor prognosis[146]. The current standard care for GBM patients involves surgical
resections which is followed by radiation and chemotherapy. TMZ is the first line
chemotherapeutic drug. However, GBM develops resistance to TMZ hence limiting effectiveness
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of the drug[147]. There are a number of mechanisms responsible for resistance observed. These
mechanisms include DNA repair systems, O6-methylguanine-DNA methyltransferase repair
mechanism, extracellular vesicle production, epigenetic modification mechanisms and
autophagy. Coupled with these mechanisms is the fact that GBM is highly heterogeneous[148,
149]. Our main aim in this research was to find out if hybrids of TMZ and NSAIDs would
overcome resistance and have a higher efficacy, i.e. more active than TMZ alone. Unfortunately,
we have not yet successfully synthesized the hybrids as explained before. Instead of the hybrids,
we used physical mixtures of TMZ and NSAIDS in the ratio of 1:1 and 1:2 respectively.

It was interesting to find out that diclofenac and oxaprozin were more active than TMZ.
TMZ had an LC50 of 0.059 while diclofenac and oxaprozin had an LC50 of 0.0139 and 0.045
respectively. Research had been previously done to find out if diclofenac could be a potential
drug against glioblastoma[150, 151]. In some cases, a combination of diclofenac and other
compounds like metformin which is the most prescribed drug in treatment of type 2 diabetes was
used[152]. Other research works focused on NSAIDs as anti-glioma agents[153]. Our findings
are in congruence with these prior research works. Diclofenac specifically, could play a role as
anti-glioblastoma agent.
It was also exciting to find out that LC50 values decreased in all the TMZ: NSAIDs
mixtures of ratio 1:1. For example, LC50 for aspirin changed from 0.2021 to 0.0844. This could
imply that hybrids with both TMZ and NSAIDs constituents could have higher efficacy
compared to individual compounds.
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In the case of TMZ: NSAIDs mixtures in the ratio 2:1 respectively, LC50 values changed
towards the LC50 value of TMZ. LC50 value of diclofenac and Oxaprozin mixtures with TMZ
increased while the LC50 value of the other NSAIDs mixtures with TMZ decreased. This was
expected since the quantity of TMZ was double the quantity of the NSAIDs.
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CHAPTER 5

CONCLUSION

In this research, we successfully synthesized novel hybrids of diclofenac and purine
amines. This was after finding out that diclofenac had more interesting and exciting
characteristics. There were observed changes in cell morphology and motility in cells treated
with diclofenac and not in cells treated with either TMZ or the other NSAIDs. Moreover,
diclofenac had the lowest LC50 value compared to all the other NSAIDs tested and TMZ. Though
we were unsuccessful in synthesizing and confirming that we synthesized novel hybrids of TMZ
and NSAIDs, we worked with TMZ and NSAIDs physical mixtures. We found out that TMZ:
NSAIDs mixtures in the ratio 1:1 respectively, had lower LC50 values compared to LC50 values
of individual compounds. In the case of TMZ: NSAIDs mixtures in the ratio 2:1 respectively, we
found out that LC50 values changed towards the LC50 value of TMZ. This was expected,
considering that TMZ was double the quantity of NSAIDs. Novel hybrid compounds of
diclofenac and purines had LC50 values significantly lower than LC50 values of individual
compounds. This suggests that hybrid compounds are more effective than individual compounds.
Future work includes confirming LC50 values, synthesizing the novel hybrids of TMZ and
NSAIDs and finding out their LC50 values. Two main research questions brought up by this
research include: what is the mechanism responsible for change in motility of cells observed in
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diclofenac and are there any proteins upregulated or downregulated? Would GBM develop
resistance against hybrids?
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